RAI Dose Linked to Secondary Primary Malignancy in Thyroid Cancer

Radioactive iodine (RAI) dose is linked to the risk for secondary primary malignancy (SPM) in patients with thyroid cancer. In 217,777 patients, the SPM rates were 7.3 and 6.56 per 1,000 person-years in the RAI and non-RAI groups, respectively; the risk increased linearly with dose in the RAI group.

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ